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tn common with many elderly women in these parts,
randmother suffered from high blood-pressure and a
eak heart. The condition was so common I always as-
umed there was something of a fashion about it.
Morabo Morojele (1)
n the past few decades, heart failure has emerged as
a major public health problem in developed coun-
tries, imposing an escalating burden on their health
are systems. In some European countries and the U.S.,
s much as 1% of the health budget is spent on the man-
gement of heart failure. In the U.S., inpatient treatment
f heart failure accounts for about U.S. $13 billion per
ear, and the amount spent on outpatient care is at least
times higher. Regretfully, most of the published data
n heart failure is based on work in Caucasian popula-
ions within the developed world, and data on its inci-
ence, prevalence, etiology, treatment, and outcome in
frica are lacking (2). As a result of improvements in the
ontrol of communicable diseases and malnutrition on
he one hand and the migration to the cities with a com-
lete change in the living habits on the other hand, car-
iovascular diseases such as hypertension and stroke are
ncreasingly recognized as significant causes of morbidity
nd mortality in most African countries (3). Nowadays,
ardiovascular diseases account for 7% to 10% of all
edical admissions to hospital, with heart failure con-
ributing to 3% to 7% (4,5). In this paper we summarize
he current state of knowledge on the etiology, treat- pent, and outcome of heart failure in Africa. Further-
ore, we propose to establish a large prospective multi-
enter multinational register to define the causes,
ontemporary treatment, and outcome of patients with
eart failure in sub-Saharan Africa. These data will assist
n developing a strategy for the early detection, treat-
ent, and prevention of heart failure on the continent.
istory of Heart Failure
esearch in Sub-Saharan Africa
he problem of heart failure has been recognized in
ub-Saharan Africa for over 60 years (6). There are at
east 11 clinical studies (Table 1) and 4 necropsy se-
ies (Table 2) that have examined the etiology of heart
ailure of hospitalized Africans in this period (4,5,7–
9). There are 3 major trends that are evident from
his experience. First, the vast majority of heart failure
ases in sub-Saharan Africa are due to the major non-
schemic causes, with rheumatic heart disease, hyper-
ensive heart disease, and cardiomyopathy accounting
or over 75% of cases in most series. Second, ischemic
eart disease remains an uncommon cause of heart
ailure with no apparent increase in its contribution to
he cases of heart failure over the past 60 years. This
bservation supports the proposal that nonischemic
eart disease is the priority for research and clinical
ntervention in Africa (20). Finally, the contribution
f cor pulmonale and pericarditis to about 20% of
ases of heart failure reflects the continuing impact of
uberculosis on heart disease on the continent. Cor
ulmonale is mainly related to post-tuberculosis lung
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October 23, 2007:1688–93 From Around the Worldamage, and pericarditis is overwhelmingly due to tubercu-
ous involvement (21). It is heartening to note, however,
hat syphilis is no longer a major factor, a development that
s probably related to the wide use of penicillin.
ontemporary Studies of
eart Failure in Sub-Saharan Africa
he majority of the clinical studies of heart failure
n sub-Saharan Africa were conducted in the
re-echocardiographic era or without the application of
chocardiography in the majority of cases (4,7–13). Oyoo
nd Ogola (5) conducted what was probably the first echo-
ardiography-based study of the etiology of heart failure in
1 consecutive patients who were admitted to the Kenyatta
ational Hospital in Nairobi, Kenya. The case definition
as based on the Framingham study, and the clinical as-
essment included echocardiography. The main etiology of
eart failure was rheumatic heart disease (32%), followed
y dilated cardiomyopathy (25%) and hypertensive heart
isease (17%) (Table 1). The relative importance of these
tiologies was similar for both genders. Ischemic heart dis-
ase accounted for only 2% of cases, a proportion that is
imilar to other parts of Africa (15).
In a study of 167 consecutive patients admitted to the
aoundé General Hospital in Cameroon and evaluated by
chocardiography, heart failure accounted for 5.8% of all
ospital admissions, rehospitalization rate was 8.3%, and
he overall in-hospital mortality was 9% (15). Forty-four
ercent of patients were in New York Heart Association
unctional class III, and 7% were in class IV. Cardiac cavi-
ies were dilated, and left ventricular ejection fraction was
ow in patients with systolic (70%) and combined systolic
nd diastolic (20%) dysfunction. Isolated diastolic heart
ailure accounted for 10% of cases. The main causes of
eart failure were hypertension (54%), cardiomyopathy
26%), and valvular heart disease (24%) (Table 1). Medical
reatment consisted of loop diuretics (90%), angiotensin-
onverting enzyme (ACE) inhibitor (65%), digoxin (31%),
nd beta-blockers (20%).
Africa is challenged by more than 30 million people
nfected with the human immunodeficiency virus (HIV).
s a consequence, HIV cardiac-related pathology, which is
ainly dilated cardiomyopathy and tuberculous pericardi-
is, is an important cause of heart failure in most African
ountries (22). The fact that HIV-associated cardiomy-
pathy has a poor prognosis, with progression to death Et
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From Around the World October 23, 2007:1688–93ithin 100 days of diagnosis in patients who are not
reated with antiretroviral drugs, and as the vast majority
f HIV patients in this continent are not able to receive
ny kind of antiretroviral therapy, this brings another
eavy burden of patients with heart failure with a very
oor prognosis.
Several papers have been published recently showing
hat a rapid epidemiologic transition is on the way in sub-
aharan Africa. The urbanization process has enormously
ncreased the prevalence of cardiovascular risk factors,
ainly hypertension, diabetes, and obesity, paving the way
or the substrate to a new epidemic in the future, the
schemic heart disease (23–25).
conomic Implications of
eart Failure in Sub-Saharan Africa
s previously alluded to, heart failure accounts for approxi-
ately 1% of the health budget in the developed countries.
uch data is not available for Africa, although some esti-
ates can be generated indirectly. For instance, approxi-
ately 3% to 7% of patients admitted to hospitals in Africa
ave heart failure (4,5). This figure is similar to the rate
escribed in the developed countries. No information is
vailable for the prevalence of heart failure in the general
opulation. It is conceivable, however, that heart failure has
t least a similar relative economic impact on health re-
ources in Africa as in the developed countries, so that 1%
f the health budget is spent on the management of pa-
Table 2 Etiology of Heart Failure in Africa: Necrops
Becker (16)
1946
South Africa
Davies (17)
1948
Uganda
Total cases (n) 332 229
Rheumatic heart disease 23.5% 3.4%
Hypertensive heart disease 28.6% 31%
Dilated cardiomyopathy* — —
Endomyocardial fibrosis — 9.6%
Cor pulmonale 10.0% 3.9%
Pericarditis — 3.5%
Syphilitic heart disease 16.9 20.9%
Ischemic heart disease 1.5 4.3%
Congenital 1.8% —
Miscellaneous† 10.3% —
*Includes peripartum cardiomyopathy; †includes anemia, ‘senile’ (or multiple
provided.ients with heart failure. lThe common causes of heart failure in sub-Saharan Af-
ica, such as rheumatic heart disease, peripartum cardio-
yopathies (26), endomyocardial fibrosis (27), and
IV-related cardiomyopathy, appear in much younger
roups than elsewhere, which puts an extra economic bur-
en as a consequence of the amount of active life years lost
or productive tasks in these patients. Importantly, learning
rom the experience of the progression of the heart failure
pidemic in the more developed countries, it is conceivable
hat the incidence of heart failure in Africa will increase
ver the next 50 years. If not addressed, the increased pro-
ortion of elderly and the escalating number of patients
ith obesity, hypertension, diabetes mellitus, metabolic
yndromes, and coronary artery disease will lead to rapidly
ncreasing numbers of patients with heart failure. For in-
tance, coronary artery disease and diastolic heart failure
due to hypertension and aging), the leading causes of heart
ailure in developed countries, are the cause for only a mi-
ority of heart failure and cardiovascular disease in general
n Africa (20). If these 2 conditions will assume the same
ole in the pathophysiology of heart failure in Africa as in
he rest of the world, the incidence and prevalence of heart
ailure in Africa may be expected to rise dramatically in the
uture.
he Opportunity
eart failure is both a preventable and treatable disease.
herefore, early diagnosis and treatment of heart failure can
ies
Higginson et al. (18)
1960
South Africa
Kallichurum (19)
1969
South Africa
537 694
32.4% 21.5%
18.6% 18.9%
14.9% 15.8%
— —
15.6% 12.0%
4.8% 7.6%
6.1% 4.8%
2.2% 2.2%
— 7.0%
3.0% 10.2%
), and undetermined cause. —  means no informationy Seread to dramatic decreases in the morbidity and mortality
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October 23, 2007:1688–93 From Around the Worldrom the disease. To illustrate such a possible effect, we will
escribe the effect of several priority interventions:
. Diagnosing and treating hypertension: During the last
few decades it was suggested that treatment of hyperten-
sion may have a significant effect on the reduction of
heart failure. This issue was shown to be more important
in African Americans who tend to develop more systolic
dysfunction due to hypertension (28). Hence, it is con-
ceivable that enhanced diagnosis and treatment of hyper-
tension may lead to a significant reduction in the rate of
heart failure in Africa.
. Diagnosing and treating rheumatic heart disease: Rheu-
matic heart disease is preventable (29,30).Many previous
studies have confirmed that administration of antibiotic
therapy to children ages 3 to 15 years will prevent the
devastating consequence of rheumatic fever, both from
the health and economic perspective. Hence, defining
the extent of the problemwill help design and implement
a prevention program for rheumatic heart disease in
children (31,32) and facilitate the planning of timely car-
diothoracic surgery for established advanced valve disease.
. Diagnosing and treating systolic heart failure: The diag-
nosis of heart failure has many implications, especially
since systolic heart failure (the form most common in
Africa, see the preceding text) is amenable to treatment.
In the last few years, much progress was achieved in the
treatment of heart failure. Many new medications were
shown to be effective in both improving symptoms and
outcome. Although most studies performed in heart fail-
ure patients pertain mostly to Caucasian patients and
patients in developed regions, there is no reason to be-
lieve that the findings are not applicable to Africans and
other human beings in general. Some studies have sug-
gested, however, that African-American patients may
have a less active renin-angiotensin system and a lower
bioavailability of nitric oxide than Caucasians, which
would justify a better response to a combination of
isosorbide dinitrate/hydralazine than ACE inhibitors
(33). For instance, the A-HeFT (African AmericanHeart
Failure Trial) study has examined the effect of adminis-
tering hydralazine and nitrates combination to African
Americans with systolic heart failure (33). This study has
demonstrated a significant improvement in all major
outcomes including mortality, readmission to hospital,
and quality of life. A pharmaco-economic analysis has lshown that the effect of this treatment will also lead to a
significant decrease in health cost by about 25% to 40%
(34). Since this treatment has been generic for20 years
now, its cost is low (U.S. $0.2/day), it is possible that its
administration in Africa will lead to similar resource
savings as in the West. However, to be effective, this
treatment should be administered to patients with heart
failure due to systolic dysfunction, again, requiring capa-
bilities to diagnose the disease. The hypothesis that an
isosorbide dinitrate/hydralazine combination is also
more effective than an ACE inhibitor should also be
tested in the near future in an African population with
systolic heart failure. Nevertheless, we are convinced
that, due to the lack of recent information on the etiology
of heart failure, a prospective multicenter registry is the
priority.
he Proposed Plan of Action:
Prospective Multicenter Registry
e propose a prospective multicenter registry that will be
mplemented in 3 stages to the study of the epidemiology
nd management of heart failure in Africa.
he first stage—preliminary definition of the problem.
here is a lack of data on the incidence, prevalence, etiol-
gy, treatment, and outcome of the disease in general and
ts geographical variation by region and country in Africa.
o better define this, we propose a simple registry of pa-
ients admitted to hospital with heart failure in Cameroon,
ozambique, Nigeria, South Africa, and other countries.
he registry will include information on the patients’
ourse before the admission, the in-hospital phase, and a
hort follow-up (6 to 12 months). It will also include 1
chocardiographic evaluation of the patients (during the
dmission).
he second stage—a larger registry and comprehensive
lan. If the preliminary stage is successful, showing that
ndeed heart failure is common in the participating centers
nd could be diagnosed with the combination of clinical
haracteristics and echocardiographic evaluation, the sec-
nd stage would include dissemination of this program to
ore centers, gradually transforming it from a scientific-
riented registry to a comprehensive diagnosis and treat-
ent program. This program will focus on diagnosing
eart failure, its existence, severity, and type and then treat-
ng it. As the program progresses, it will strive to establish
ong-standing follow-up of patients on an outpatient basis.
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From Around the World October 23, 2007:1688–93s this registry develops, it could be turned into an educa-
ional tool through which resources will be progressively
hifted toward peripheral community medical centers
here better diagnosis and treatment of heart failure are
xpected to have a significant effect on health and health
conomics.
uture steps. After defining more clearly the etiology,
athophysiology, course, and treatment of heart failure in
frica, a 2-pronged approach is proposed:
First, a vast area of research is the therapeutic approach
f heart failure in Africa. As very few clinical trials testing
reatment of heart failure were previously done in Africa,
ne could question if what is accepted as a standard thera-
eutic approach is also effective in Sub-Saharan Africa. For
xample, the low renin levels already described in the Afri-
an populations could justify that a beta-blocker, being
ore effective than an ACE inhibitor, should be used be-
ore the last one as was previously described by some of us
35). The same could be tested for the possible benefit of
he isosorbide dinitrate/hydralazine compared with the use
f an ACE inhibitor.
Another area of future research in a continent with very
ew human and material resources could be the use of inno-
ative and low-cost approaches to control patients with
ardiac failure. A wide camp of collaborative studies and
artnerships with groups of researchers from other parts of
he world is open behind us.
We will attempt to explore in more detail the treatment
f heart failure, with particular relevance to diseases that are
ommon in Africa, such as postpartum cardiomyopathy
nd endomyocardial fibrosis. Some heart failure syndromes,
uch as hypertensive heart disease, may have a different
ourse and pathophysiology in Africa and, hence, may need
ifferent treatment (28).
Second, prevention. As alluded to in the preceding text,
he prevention of heart failure in Africa may require a dif-
erent approach from that adopted in developed regions
ecause of differences in the etiology of heart disease in
frica, which are largely due to nonischemic causes (20).
herefore, although coronary artery disease is expected to
ncrease dramatically in the future in the short term, pre-
ention of ischemic heart disease may be expected to have a
maller role in the prevention of heart failure in Africa
hile having a dramatic effect in developed regions. By
ontrast, the treatment of hypertension and prevention of
heumatic fever will have a larger effect in Africa (20).
1onclusions
eart failure is an important cause of morbidity and mor-
ality in Africa. While it is apparent that the causes of heart
ailure are largely nonischemic in Africans, the incidence,
revalence, treatment, and outcome are not defined. By
omparing the percent of hospital admissions in Africa and
he developed world, it is likely that heart failure has a sig-
ificant effect on the health and health economics in Africa.
fforts should be put forward to characterize this disease
nd ultimately improve its detection, treatment, and possi-
ly prevention.
lease note: Dr. Cotter is currently affiliated with Momentum-Research Inc.,
urham, North Carolina.
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